(Q33407102)

English

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

E Zucca

8

0 references

author name string

F Hitz

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Fischer

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Th Pabst

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Caspar

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Berthod

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Eckhardt

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Berardi Vilei

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

U Mey

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

17 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1033-1040

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Management of the frail person with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Lifetime risks of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Comorbidity and functional status are independent in older cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Measuring comorbidity in older cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Measurement and impact of comorbidity in older cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1751-Z

21 January 2018

Identifiers

10.1007/S00277-013-1751-Z

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33407102&oldid=1749478246"